Induced pluripotent stem cells in cardiovascular medicine

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Induced pluripotent stem (iPS) cells are generated by reprogramming human somatic cells through the forced expression of several embryonic stem (ES) cell-specific transcription factors. The potential of iPS cells is having a significant impact on regenerative medicine, with the promise of infinite self-renewal, differentiation into multiple cell types, and no problems concerning ethics or immunological rejection. Human iPS cells are currently generated by transgene introduction principally through viral vectors, which integrate into host genomes, although the associated risk of tumorigenesis is driving research into nonintegration methods. Techniques for pluripotent stem cell differentiation and purification to yield cardiomyocytes are also advancing constantly. Although there remain some unsolved problems, cardiomyocyte transplantation may be a reality in the future. After those problems will be solved, applications of human iPS cells in human cardiovascular regenerative medicine will be envisaged for the future. Furthermore, iPS cell technology has generated new human disease models using disease-specific cells. This paper summarizes the progress of iPS cell technology in cardiovascular research.

Original languageEnglish
Article number348960
JournalStem Cells International
DOIs
Publication statusPublished - 2011

Fingerprint

Induced Pluripotent Stem Cells
Medicine
Regenerative Medicine
Cardiac Myocytes
Technology
Pluripotent Stem Cells
Embryonic Stem Cells
Transgenes
Research
Ethics
Cell Differentiation
Carcinogenesis
Transcription Factors
Transplantation
Genome

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Induced pluripotent stem cells in cardiovascular medicine. / Egashira, Toru; Yuasa, Shinsuke; Fukuda, Keiichi.

In: Stem Cells International, 2011.

Research output: Contribution to journalArticle

@article{afec1bd47fb94579a5810913976845db,
title = "Induced pluripotent stem cells in cardiovascular medicine",
abstract = "Induced pluripotent stem (iPS) cells are generated by reprogramming human somatic cells through the forced expression of several embryonic stem (ES) cell-specific transcription factors. The potential of iPS cells is having a significant impact on regenerative medicine, with the promise of infinite self-renewal, differentiation into multiple cell types, and no problems concerning ethics or immunological rejection. Human iPS cells are currently generated by transgene introduction principally through viral vectors, which integrate into host genomes, although the associated risk of tumorigenesis is driving research into nonintegration methods. Techniques for pluripotent stem cell differentiation and purification to yield cardiomyocytes are also advancing constantly. Although there remain some unsolved problems, cardiomyocyte transplantation may be a reality in the future. After those problems will be solved, applications of human iPS cells in human cardiovascular regenerative medicine will be envisaged for the future. Furthermore, iPS cell technology has generated new human disease models using disease-specific cells. This paper summarizes the progress of iPS cell technology in cardiovascular research.",
author = "Toru Egashira and Shinsuke Yuasa and Keiichi Fukuda",
year = "2011",
doi = "10.4061/2011/348960",
language = "English",
journal = "Stem Cells International",
issn = "1687-9678",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Induced pluripotent stem cells in cardiovascular medicine

AU - Egashira, Toru

AU - Yuasa, Shinsuke

AU - Fukuda, Keiichi

PY - 2011

Y1 - 2011

N2 - Induced pluripotent stem (iPS) cells are generated by reprogramming human somatic cells through the forced expression of several embryonic stem (ES) cell-specific transcription factors. The potential of iPS cells is having a significant impact on regenerative medicine, with the promise of infinite self-renewal, differentiation into multiple cell types, and no problems concerning ethics or immunological rejection. Human iPS cells are currently generated by transgene introduction principally through viral vectors, which integrate into host genomes, although the associated risk of tumorigenesis is driving research into nonintegration methods. Techniques for pluripotent stem cell differentiation and purification to yield cardiomyocytes are also advancing constantly. Although there remain some unsolved problems, cardiomyocyte transplantation may be a reality in the future. After those problems will be solved, applications of human iPS cells in human cardiovascular regenerative medicine will be envisaged for the future. Furthermore, iPS cell technology has generated new human disease models using disease-specific cells. This paper summarizes the progress of iPS cell technology in cardiovascular research.

AB - Induced pluripotent stem (iPS) cells are generated by reprogramming human somatic cells through the forced expression of several embryonic stem (ES) cell-specific transcription factors. The potential of iPS cells is having a significant impact on regenerative medicine, with the promise of infinite self-renewal, differentiation into multiple cell types, and no problems concerning ethics or immunological rejection. Human iPS cells are currently generated by transgene introduction principally through viral vectors, which integrate into host genomes, although the associated risk of tumorigenesis is driving research into nonintegration methods. Techniques for pluripotent stem cell differentiation and purification to yield cardiomyocytes are also advancing constantly. Although there remain some unsolved problems, cardiomyocyte transplantation may be a reality in the future. After those problems will be solved, applications of human iPS cells in human cardiovascular regenerative medicine will be envisaged for the future. Furthermore, iPS cell technology has generated new human disease models using disease-specific cells. This paper summarizes the progress of iPS cell technology in cardiovascular research.

UR - http://www.scopus.com/inward/record.url?scp=84855290536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855290536&partnerID=8YFLogxK

U2 - 10.4061/2011/348960

DO - 10.4061/2011/348960

M3 - Article

JO - Stem Cells International

JF - Stem Cells International

SN - 1687-9678

M1 - 348960

ER -